drugset

drugset / Trial / NCT07115004

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT07115004 ↗

Phase 3 Recruiting 60 enrolled Vega Therapeutics, Inc

NaSequentialOpen-labelTreatment

Summary

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Timeline

Start: 2025-10-15
Primary completion: 2028-10
Completion: 2028-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VGA039	Unknown	—	Subcutaneous

Indications